Evidence map›Paper›PMID 23129577›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival.

Theresa D Carr, John DiGiovanni, Christopher J Lynch, Lisa M Shantz

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Clinical, cosmetic and investigational dermatology · 2022
    Article
  10. Nicotinamide Mononucleotide Combined WithFrontiers in pharmacology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during Myelination.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Theresa D CarrDepartment of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.
John DiGiovanni
Christopher J Lynch
Lisa M Shantz
Pennsylvania State University · US

Funding

Mechanisms of IGF-1 Tumor Promotion in Mouse SkinR01CA037111 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIGIOVANNI, JOHN · 1985 to 2010
$2.8M
Role of Leucine Metabolism in Leucine SignalingR01DK062880 · NIDDK · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LYNCH, CHRISTOPHER JOHN · 2003 to 2010
$2.8M
mTOR-dependent pathways in skin carcinogenesisR21ES019242 · NIEHS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SHANTZ, LISA M · 2010 to 2011
$420k
mTOR signaling in keratinocyte UVB responseF30ES019809 · NIEHS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CARR, THERESA DIANE · 2011 to 2015
$159k
Evaluation of mTOR as a chemoprevention target in skin cancerR03CA133945 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SHANTZ, LISA M · 2008 to 2009
$154k
NCI NIH HHS CA133945NCI NIH HHS CA37111NCI NIH HHS R01 CA037111NCI NIH HHS R03 CA133945NIDDK NIH HHS DK62880NIDDK NIH HHS R01 DK062880NIEHS NIH HHS ES19242NIEHS NIH HHS F30 ES019809NIEHS NIH HHS F30 ES19809NIEHS NIH HHS R21 ES019242
6 · The paper itself

Abstract

UV radiation is the major risk factor for developing skin cancer, the most prevalent cancer worldwide. Several studies indicate that mTOR signaling is activated by UVB and may play an important role in skin tumorigenesis. mTOR exists in two functionally and compositionally distinct protein complexes: the rapamycin-sensitive mTOR complex 1 (mTORC1) and the rapamycin-resistant mTOR complex 2 (mTORC2). The purpose of these studies was to investigate the roles of the two mTOR complexes in UVB-mediated proliferation and apoptosis in the skin. We used rapamycin, a pharmacologic inhibitor of mTORC1, and an inducible mTOR-deficient (K5-CreER(T2);mTOR(fl/fl)) mouse model that allows epidermal-specific disruption of mTOR following topical treatment with 4-hydroxytamoxifen (4OHT). Rapamycin blocked UVB-induced phosphorylation of S6K, the downstream target of mTORC1, and significantly reduced UVB-stimulated epidermal proliferation and cell-cycle progression, but had no effect on cell death. In contrast, mTOR deletion, which attenuated UVB-induced phosphorylation of both S6K and the mTORC2 target AKT(Ser473), significantly increased apoptosis both in vivo and in keratinocyte cultures, in addition to reducing hyperproliferation following UVB irradiation. The role of mTORC2 in UVB-induced prosurvival signaling was verified in Rictor(-/-) mouse embryo fibroblasts, which lack functional mTORC2 and were more sensitive to UVB-induced apoptosis than controls. These studies show that mTORC1 and mTORC2 play unique but complementary roles in controlling proliferation and apoptosis in the skin. Our findings underscore the importance of both mTOR complexes in mediating UVB-induced signaling in keratinocytes and provide new insight into the pathogenesis of skin cancer.

Indexed as

Gene Expression Regulation, NeoplasticUltraviolet RaysAnimalsCell CycleCell Line, TumorCell ProliferationCell SurvivalFibroblastsFlow CytometryKeratinocytesMiceMice, TransgenicPhosphorylationRibosomal Protein S6 KinasesRisk FactorsSignal TransductionmTOR protein, mouseRibosomal Protein S6 KinasesTOR Serine-Threonine Kinases

Identifiers

PMID23129577
PMCPMC3518591
OpenAlexW2116153244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.